ActivistsInvestorsTrumpPoliticiansSerenityCitriniBurrySemianalysisSwingTradeArbitrageSearch

$AUPH:NASDAQ · Aurinia Pharmaceuticals Inc - US

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan.

More about this company

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.

Sector: health

Conviction from: NASDAQ

52-week range: 13.5219.25

2 tracked filer(s) hold this · 2 opened, 0 added, 0 trimmed in 30-SEP-2026

Aggregate 13FScore 68 — mean of 2 scored holder(s) · buyers (new/add) avg 68. Higher = the smart money in this name has the better track record.

Filer13FScoreThis quarterSharesValue% of their book
Paul Tudor Jones / Tudor61New buy47,854$774,9960.0%
Steve Cohen / Point7275New buy223,907$3,626,1740.0%

Beyond 13F — activists, insiders, politicians & research

Activist 13D filings daily digest →

FiledFormActivist% of classConviction
2026-03-25SCHEDULE 13D/ATANG CAPITAL MANAGEMENT LLC9.2%Medfiling
2026-03-03SCHEDULE 13D/ATANG CAPITAL MANAGEMENT LLC9.2%Medfiling

Insider open-market buys daily digest →

FiledInsiderRoleSharesValue
2026-03-03TANG KEVINdirector900,000$12,688,806Form 4

Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-11-17.